{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:11:30Z","timestamp":1785899490540,"version":"3.56.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600443"],"award-info":[{"award-number":["81600443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Mucosal deficiency is one of the most challenging conditions in patients with acute severe ulcerative colitis (ASUC). Intravenous corticosteroids (CS) are the first-line treatment, with infliximab (IFX) used as a rescue therapy. However, the efficacy remains unsatisfactory. We investigated whether CS combined with IFX as first-line therapy would improve outcomes in patients with ASUC with mucosal deficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was performed at a tertiary inflammatory bowel disease center. The primary outcomes included clinical remission, endoscopic improvement, and endoscopic remission at week 14. The secondary outcomes included the colectomy rate within 90\u2009days and durable clinical remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 43 patients with ASUC with mucosal deficiency were included in the analysis (25 in the CS combined with the IFX group and 18 in the CS sequential IFX group). At week 14, endoscopic improvement was observed in 21 of 25 patients (84.0%) receiving the CS combined with the IFX regimen, compared to 9 of 18 (50.0%) patients receiving the CS sequential IFX regimen (<jats:italic>p<\/jats:italic>\u2009=\u20090.017). Durable clinical remission rates were significantly higher in the combined group than in the sequential group (85.7% vs. 35.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). There was no statistically significant difference between the two groups in terms of clinical and endoscopic remission at week 14 or colectomy rate within 90\u2009days. Multivariate analysis confirmed that the CS combined with the IFX regimen was an independent predictive factor for a higher endoscopic improvement rate at week 14 (odds ratio (OR) 8.428, 95%confidence interval (CI) 1.539\u201346.153, <jats:italic>p<\/jats:italic>\u2009=\u20090.014) and a higher durable clinical remission rate (OR 10.800, 95%CI 2.095\u201355.666, <jats:italic>p<\/jats:italic>\u2009=\u20090.004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CS combined with IFX as first-line therapy may be an effective induction strategy in patients with ASUC with mucosal deficiency. Further large-scale, multicenter prospective studies are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1442519","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:50:15Z","timestamp":1732078215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Corticosteroids combined with infliximab vs. corticosteroids sequential infliximab for acute severe ulcerative colitis with mucosal deficiency: a retrospective study"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaolei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and Meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high-dose Tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/ajg.2017.282","article-title":"We are still talking about Cylosporin vs. infliximab in steroid resistant acute severe ulcerative colitis","volume":"112","author":"Bernstein","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and Meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/ibd\/izy383","article-title":"Systematic review and Meta-analysis: optimal salvage therapy in acute severe ulcerative colitis","volume":"25","author":"Choy","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/apt.13670","article-title":"Review article: acute severe ulcerative colitis\u2014evidence-based consensus statements","volume":"44","author":"Chen","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the Management of Moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ueg2.12442","article-title":"Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies","volume":"11","author":"Calm\u00e9jane","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial: Tofacitinib in ASUC","volume":"119","author":"Singh","year":"2023","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1442519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T04:50:19Z","timestamp":1732078219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1442519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":20,"alternative-id":["10.3389\/fmed.2024.1442519"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1442519","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"article-number":"1442519"}}